Dashboard
Manage Tickers

RNAAvidity Biosciences, Inc.

Nasdaq aviditybiosciences.com


$ 40.76 $ 0.30 (0.74 %)    

Monday, 09-Sep-2024 15:59:59 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 455.25 $ 5.77 (1.29 %)
DIA $ 409.08 $ 4.58 (1.13 %)
SPY $ 546.60 $ 6.05 (1.12 %)
TLT $ 99.96 $ 0.43 (0.43 %)
GLD $ 231.58 $ 0.97 (0.42 %)
$ 40.76
$ 40.99
$ 40.77 x 100
$ 40.81 x 100
$ 40.65 - $ 41.98
$ 4.83 - $ 48.80
772,871
na
4.48B
$ 1.20
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-09-2024 06-30-2024 10-Q
2 05-09-2024 03-31-2024 10-Q
3 02-28-2024 12-31-2023 10-K
4 11-08-2023 09-30-2023 10-Q
5 08-08-2023 06-30-2023 10-Q
6 05-09-2023 03-31-2023 10-Q
7 02-28-2023 12-31-2022 10-K
8 11-08-2022 09-30-2022 10-Q
9 08-09-2022 06-30-2022 10-Q
10 05-10-2022 03-31-2022 10-Q
11 03-01-2022 12-31-2021 10-K
12 11-09-2021 09-30-2021 10-Q
13 08-09-2021 06-30-2021 10-Q
14 05-12-2021 03-31-2021 10-Q
15 03-15-2021 12-31-2020 10-K
16 11-10-2020 09-30-2020 10-Q
17 08-11-2020 06-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

fulcrum-therapeutics-upgraded-bofa-debates-pivotal-study-success-for-losmapimod-in-rare-genetic-muscle-disease
Fulcrum Therapeutics Upgraded: BofA Debate...
09/09/2024 18:28:05

BofA Securities upgraded Fulcrum Therapeutics ahead of its phase 3 losmapimod results for Facioscapulohumeral muscular dystroph...

cantor-fitzgerald-reiterates-overweight-on-avidity-biosciences-maintains-96-price-target
Cantor Fitzgerald Reiterates Overweight on...
09/09/2024 16:08:41

Cantor Fitzgerald analyst Eric Schmidt reiterates Avidity Biosciences (NASDAQ:RNA) with a Overweight and maintains $96 price...

deep-dive-into-avidity-biosciences-stock-analyst-perspectives-10-ratings
Deep Dive Into Avidity Biosciences Stock: ...
08/28/2024 13:00:18

barclays-initiates-coverage-on-avidity-biosciences-with-overweight-rating-announces-price-target-of-63
Barclays Initiates Coverage On Avidity Bio...
08/28/2024 12:28:32

Barclays analyst Gena Wang initiates coverage on Avidity Biosciences (NASDAQ:RNA) with a Overweight rating and announces Pri...

evercore-isi-group-maintains-outperform-on-avidity-biosciences-lowers-price-target-to-53
Evercore ISI Group Maintains Outperform on...
08/26/2024 13:14:51

Evercore ISI Group analyst Josh Schimmer maintains Avidity Biosciences (NASDAQ:RNA) with a Outperform and lowers the price t...

reported-earlier-avidity-biosciences-prices-3001m-upsized-public-offering-of-7320000-common-stock-at-41share
Reported Earlier, Avidity Biosciences Pric...
08/15/2024 07:00:26

The gross proceeds to Avidity from the offering, before deducting the underwriting discounts and commissions and other offering...

avidity-biosciences-proposes-250m-public-offering-of-common-stock
Avidity Biosciences Proposes $250M Public ...
08/13/2024 20:24:15

Avidity Biosciences, Inc. (NASDAQ:RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics cal...

needham-reiterates-buy-on-avidity-biosciences-maintains-60-price-target
Needham Reiterates Buy on Avidity Bioscien...
08/13/2024 10:11:14

Needham analyst Joseph Stringer reiterates Avidity Biosciences (NASDAQ:RNA) with a Buy and maintains $60 price target.

the-analyst-landscape-7-takes-on-avidity-biosciences
The Analyst Landscape: 7 Takes On Avidity ...
08/12/2024 16:00:29

evercore-isi-group-maintains-outperform-on-avidity-biosciences-raises-price-target-to-54
Evercore ISI Group Maintains Outperform on...
08/12/2024 14:04:12

Evercore ISI Group analyst Josh Schimmer maintains Avidity Biosciences (NASDAQ:RNA) with a Outperform and raises the price t...

chardan-capital-maintains-buy-on-avidity-biosciences-raises-price-target-to-60
Chardan Capital Maintains Buy on Avidity B...
08/09/2024 21:52:25

Chardan Capital analyst Keay Nakae maintains Avidity Biosciences (NASDAQ:RNA) with a Buy and raises the price target from $4...

avidity-biosciences-q2-eps-065-beats-079-estimate-collaboration-revenue-204m-miss-264m-estimate
Avidity Biosciences Q2 EPS $(0.65) Beats $...
08/09/2024 20:12:37

Avidity Biosciences (NASDAQ:RNA) reported quarterly losses of $(0.65) per share which beat the analyst consensus estimate of $(...

expedia-posts-upbeat-earnings-joins-akamai-technologies-trade-desk-dxc-technology-and-other-big-stocks-moving-higher-on-friday
Expedia Posts Upbeat Earnings, Joins Akama...
08/09/2024 16:51:33

avidity-biosciences-says-data-suggest-del-zota-has-potential-to-change-treatment-paradigm-and-course-of-disease-for-patients-with-duchenne-muscular-dystrophy-mutations-amenable-to-exon-44-skipping
Avidity Biosciences Says Data Suggest del-...
08/09/2024 11:15:59

AOC 1044 demonstrated favorable safety and tolerability. Avidity also announced delpacibart zotadirsen as the approved internat...

genedx-leads-russell-2000-this-year-as-it-shifts-to-more-comprehensive-genetic-testing-corrected
GeneDx Leads Russell 2000 This Year As It ...
08/02/2024 18:06:16

GeneDx Holdings Corp. (NASDAQ: WGS) has soared 1,101% this year, attributed to its mix shift towards exome/genome testing and r...

genedx-leads-russell-2000-this-year-as-it-shifts-to-more-comprehensive-genetic-testing-corrected
GeneDx Leads Russell 2000 This Year As It ...
08/02/2024 18:06:16

GeneDx Holdings Corp. (NASDAQ: WGS) has soared 1,101% this year, attributed to its mix shift towards exome/genome testing and r...

top-performing-industry-etfs-in-june-software-leads-returns-chipmakers-attract-most-inflows
Top Performing Industry ETFs In June: Soft...
07/01/2024 17:38:29

June saw gains in the U.S. stock market, with tech and biotech leading the way. Semiconductor ETFs saw strong inflows, while ut...

rna---analyzing-avidity-biosciencess-short-interest
(RNA) - Analyzing Avidity Biosciences's Sh...
06/20/2024 15:45:19

avidity-biosciences-and-cleanspark-were-among-the-10-biggest-mid-cap-stock-gainers-last-week-june-9-june-15-are-these-in-your-portfolio
Avidity Biosciences And CleanSpark Were Am...
06/16/2024 18:25:10

Top mid-cap performers: Avidity Biosciences, Iris Energy, Hims & Hers Health, John Wiley & Sons, Element Solutions, Cle...

adobe-avidity-biosciences-and-3-stocks-to-watch-heading-into-friday
Adobe, Avidity Biosciences And 3 Stocks To...
06/14/2024 10:08:09

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION